Efficacy and safety of alirocumab among individuals with diabetes mellitus and atherosclerotic cardiovascular disease in the ODYSSEY phase 3 trials

AIMS: Individuals with both diabetes mellitus (DM) and atherosclerotic cardiovascular disease (ASCVD) are at very high risk of cardiovascular events. This post‐hoc analysis evaluated efficacy and safety of the PCSK9 inhibitor alirocumab among 984 individuals with DM and ASCVD pooled from 9 ODYSSEY P...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Diabetes Obes Metab
Autori principali: Ganda, Om P., Plutzky, Jorge, Sanganalmath, Santosh K., Bujas‐Bobanovic, Maja, Koren, Andrew, Mandel, Jonas, Letierce, Alexia, Leiter, Lawrence A.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Blackwell Publishing Ltd 2018
Soggetti:
Original Articles
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6175384/
https://ncbi.nlm.nih.gov/pubmed/29802688
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.13384
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi